Results from Cox regression models in subgroups considering both the presence of CAD versus PAD and the presence of T2DM
| CAD | PAD | |||
| T2DM− | T2DM+ | T2DM− | T2DM+ | |
| 3-point MACE | – | 1.57 (1.21 to 2.03) | 1.50 (1.09 to 2.06) | 2.94 (2.18 to 3.97) |
| 3-point MACE* | – | 1.27 (0.93 to 1.79) | 1.28 (0.91 to 1.79) | 2.18 (1.49 to 3.18] |
| Vascular mortality | – | 2.00 (1.40 to 2.85) | 1.46 (0.91 to 2.33) | 3.22 (2.13 to 4.89) |
| Vascular mortality* | – | 1.70 (1.08 to 2.70) | 1.30 (0.78 to 2.16) | 2.13 (1.25 to 3.63) |
| Stroke | – | 1.36 (0.84 to 2.20) | 1.73 (1.01 to 2.97) | 2.24 (1.93 to 5.43) |
| Stroke* | – | 1.05 (0.57 to 1.92) | 1.47 (0.82 to 2.61) | 2.00 (1.02 to 3.91) |
| MCI | – | 1.32 (0.84 to 2.08) | 2.32 (1.48 to 3.65) | 3.03 (1.86 to 4.95) |
| MCI* | – | 1.17 (0.68 to 2.01) | 1.88 (1.15 to 3.07) | 2.44 (1.33 to 4.49] |
| All-cause mortality | – | 1.60 (1.29 to 2.00) | 1.69 (1.29 to 2.20) | 2.67 (2.04 to 3.48) |
| All-cause mortality* | – | 1.30 (0.98 to 1.72) | 1.37 (1.03 to 1.82) | 1.58 (1.13 to 2.20) |
*Adjustments were made for age, gender, BMI, history of smoking, arterial hypertension, systolic blood pressure, LDL cholesterol, HDL cholesterol, HbA1c, eGFR, use of statins, ACE-inhibitors/ATII RBA and aspirin/clopidogrel.
ACE, angiotensin converting enzyme; ATII RBA, ATII receptor blocking agents; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; MCI, myocardial infarction; PAD, peripheral artery disease; 3-point MACE, major cardiovascular endpoint (including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke); T2DM, type 2 diabetes mellitus.